TEAD4 Transcription Factor: Master Regulator of Development, Homeostasis and Oncogenesis

Concept

Transcriptional Enhanced Associate Domain 4 (TEAD4) is a pivotal member of the TEAD family of transcription factors, serving as a central molecular switch that orchestrates mammalian early embryonic development, adult tissue homeostasis, organ regeneration and tumor progression. Defined by a highly conserved N-terminal TEA domain—an approximately 68-amino-acid DNA-binding module with a unique cloverleaf-like 3D conformation—TEAD4 mediates sequence-specific binding to MCAT (5'-CATTCC-3') and GTIIC (5'-GGAATG-3') cis-regulatory elements in the genome. Its C-terminal YAP/TAZ-binding domain forms a hydrophobic pocket for interaction with Hippo pathway coactivators, a key determinant of TEAD4’s transcriptional activity.

Dynamic post-translational modifications (PTMs), most notably S-palmitoylation at the Cys367 residue, fine-tune TEAD4’s subcellular localization, protein stability and functional output, with palmitoylation levels directly correlating with its transcriptional activity. Aberrant TEAD4 overexpression and hyperactivation are tightly linked to the initiation and progression of multiple human malignancies, establishing TEAD4 as a promising therapeutic target for anticancer drug development. ANT BIO PTE. LTD.’s UA sub-brand—specializing in high-quality recombinant proteins—offers a human TEAD4(YBD) His Tag Protein, an essential research tool for dissecting TEAD4’s molecular mechanisms and advancing translational research into TEAD4-targeted therapies.

Research Frontier

Recent advances in structural biology, developmental biology and cancer research have uncovered the multifaceted and context-dependent functions of TEAD4, positioning it as a leading research hotspot in basic and translational life science. Cutting-edge structural studies using X-ray crystallography and cryo-electron microscopy have resolved the precise DNA-binding interface of TEAD4—including the critical histidine residue at position 51—and the structural basis of its interaction with YAP/TAZ, revealing subtle functional divergences from other TEAD family members and providing a rational structural framework for the design of selective TEAD4 modulators.

In cancer research, clinical and preclinical investigations have confirmed TEAD4 as a key oncogenic transcription factor, frequently overexpressed in gastric cancer, hepatocellular carcinoma, breast cancer and colorectal cancer, with its expression levels correlating strongly with tumor aggressiveness, metastatic potential and poor patient prognosis. Novel research has further elucidated TEAD4’s role in tumor metabolic reprogramming—driving the Warburg effect via upregulation of glycolysis-related genes—and tumor microenvironment remodeling, expanding our understanding of its pro-tumorigenic mechanisms beyond classical Hippo-YAP/TAZ signaling integration.

TEAD4-targeted therapeutic development has also entered an era of rapid innovation, with small-molecule inhibitors (e.g., VT104, K-975) that target the TEAD4 palmitoylation pocket and peptide inhibitors (e.g., TED-347) that disrupt TEAD4-YAP/TAZ protein-protein interactions demonstrating potent antitumor efficacy in preclinical models. Several TEAD4-targeted small molecules have now advanced to Phase I/II clinical trials, with TEAD4 expression emerging as a predictive biomarker for patient stratification and treatment response. Additionally, next-generation strategies—including PROTAC degraders, allosteric inhibitors, bispecific molecules and tissue-specific delivery systems—are being explored to address critical challenges such as off-target toxicity, poor selectivity and drug resistance, representing the cutting edge of TEAD4 research.

Research Significance

Unraveling the molecular mechanisms and biological functions of TEAD4 holds profound scientific and clinical significance across multiple research disciplines, with far-reaching implications for developmental biology, regenerative medicine and oncology:

1. Advancing Developmental Biology: TEAD4 is a master regulator of the first cell fate decision in mammalian embryos and trophectoderm lineage specification during blastocyst formation. In-depth study of TEAD4 clarifies the molecular basis of early embryonic development and embryo implantation, providing critical insights into the pathogenesis of early pregnancy loss and offering potential therapeutic targets for reproductive disorders.
2. Guiding Regenerative Medicine: TEAD4 plays an indispensable role in adult tissue homeostasis and organ regeneration (liver, skin, heart), with its activity tightly regulated by mechanical signals and the Hippo pathway. Spatiotemporal and tissue-specific modulation of TEAD4 activity represents a novel strategy for promoting tissue repair and regeneration, opening new avenues for the treatment of organ injury and degenerative diseases.
3. Driving Anticancer Drug Development: As a validated oncogenic transcription factor, TEAD4 integrates multiple oncogenic signaling pathways to drive tumorigenesis, metastasis and chemoresistance. Targeting TEAD4 provides a novel and promising approach for cancer therapy, particularly for tumors with hyperactivated Hippo-YAP/TAZ signaling, offering new treatment options for patients with refractory malignancies such as gastric and liver cancer.
4. Enabling Precision Oncology: TEAD4 expression levels and PTM status serve as predictive biomarkers for cancer prognosis and therapeutic response. Identifying TEAD4 as a biomarker enables rational patient stratification for TEAD4-targeted therapies, laying the foundation for precision oncology and improving the efficacy and safety of cancer treatment.
5. Elucidating Signaling Network Cross-Talk: TEAD4 acts as a nodal point integrating Hippo signaling with other oncogenic and developmental pathways. Studying TEAD4 enhances our understanding of inter-pathway cross-talk, providing a more comprehensive view of cellular regulatory networks in health and disease.

High-purity recombinant TEAD4 protein is a foundational tool for all these research directions, and its availability directly determines the depth, reliability and translational potential of TEAD4-related research.

Related Mechanisms and Product Applications

Core Molecular Mechanisms and Biological Functions of TEAD4

1. Structural Features and Post-Translational Regulation

TEAD4’s functional activity is governed by its unique structural architecture and dynamic post-translational modifications (PTMs):

• TEA Domain: The conserved N-terminal DNA-binding module with a cloverleaf-like conformation mediates specific binding to MCAT and GTIIC genomic elements, with the H51 residue playing a decisive role in binding specificity and affinity.
• YAP/TAZ-Binding Domain (YBD): The C-terminal hydrophobic pocket forms a specific interaction interface with Hippo pathway effectors YAP and TAZ, the primary coactivators required for TEAD4-mediated transcriptional activation.
• Dynamic PTMs: S-palmitoylation (predominantly at Cys367), phosphorylation, acetylation and SUMOylation dynamically regulate TEAD4’s subcellular localization, protein stability and transcriptional activity. Palmitoylation is the most well-characterized modification, with its level positively correlating with TEAD4’s ability to drive target gene expression.

2. Context-Dependent Biological Functions

TEAD4 exerts highly tissue-specific and context-dependent functions across physiological and pathological processes:

• Early Embryonic Development: TEAD4 orchestrates the first cell fate decision in mammalian embryos, driving trophectoderm (TE) lineage specification by activating TE-specific transcription factors (Cdx2, Gata3, Eomes). TEAD4 deficiency results in mouse embryo arrest at the blastocyst stage and loss of trophoblast stem cells, mimicking human embryo implantation failure. Its activity is tightly regulated by Hippo signaling and mechanical tension—outer embryonic cells exhibit inhibited Hippo signaling, allowing YAP/TAZ nuclear translocation and TEAD4 activation, while inner cells have active Hippo signaling, sequestering YAP/TAZ in the cytoplasm and repressing TEAD4 function.
• Adult Tissue Homeostasis and Regeneration: TEAD4 regulates hepatocyte proliferation during liver regeneration, epidermal stem cell maintenance and differentiation in skin, and cardiomyocyte remodeling in the heart. Its activity is modulated by the mechanical properties of the extracellular matrix, with stiff substrates promoting TEAD4-YAP complex formation and nuclear translocation to enhance proliferation, and soft substrates inhibiting this pathway to drive differentiation. TEAD4 exhibits distinct functions across cell types: epithelial cells (proliferation/differentiation), stromal cells (fibrosis/matrix remodeling) and endothelial cells (angiogenesis).
• Tumorigenesis and Progression: TEAD4 acts as an oncogenic transcription factor by integrating Hippo-YAP/TAZ signaling with other oncogenic pathways to activate pro-tumorigenic gene programs. It enhances tumor cell migration and invasion via upregulation of MMP family proteins and EMT transcription factors (Twist, Slug); promotes proliferation and chemoresistance through regulation of cell cycle genes (c-Myc, cyclin D1); drives metabolic reprogramming by inducing glycolysis-related genes (GLUT1, HK2, LDHA); and remodels the tumor microenvironment via stromal factors (CTGF, CYR61) to create a pro-tumor niche.

3. TEAD4-Targeted Therapeutic Strategies

Current TEAD4-targeted anticancer strategies focus on three core approaches, with ongoing development of next-generation innovative methods to overcome existing limitations:

• Direct Transcriptional Inhibition: Small molecules (VT104, K-975) competitively bind the TEAD4 palmitoylation pocket, inducing conformational changes that suppress its transcriptional activity and target gene expression.
• Cofactor Interaction Disruption: Peptide and small-molecule inhibitors (TED-347) specifically block the TEAD4-YAP/TAZ protein-protein interaction, abrogating TEAD4-mediated transcriptional activation without affecting other TEAD family members.
• Gene Expression Silencing: siRNA, shRNA and antisense oligonucleotides selectively reduce TEAD4 expression, inhibiting tumor growth and metastasis in preclinical models.
• Next-Generation Strategies: PROTAC degraders, allosteric inhibitors, bispecific molecules and tissue-specific delivery systems are being developed to address off-target toxicity, poor selectivity and drug resistance—key challenges facing current TEAD4-targeted therapies.

TEAD4(YBD), His Tag Protein from ANT BIO PTE. LTD.: Core Applications and Research Value

ANT BIO PTE. LTD.’s UA sub-brand offers a high-purity Human TEAD4(YBD), His Tag Protein (Catalog No.: UA080035), expressed in E. coli with an unconjugated His tag. This recombinant protein is produced under rigorous quality control standards, ensuring high purity, structural integrity and biological activity, and serves as an indispensable research tool for investigating TEAD4’s molecular mechanisms and validating TEAD4-targeted therapeutic strategies.

Key Research Applications

1. Structural Biology Studies: Used for X-ray crystallography and cryo-electron microscopy to resolve the 3D structure of the TEAD4 YAP/TAZ-binding domain (YBD) and its complexes with YAP/TAZ or small-molecule inhibitors. This research elucidates the molecular basis of protein-protein and protein-small molecule interactions, providing a structural framework for rational design of TEAD4-targeted therapeutics.
2. Protein-Protein Interaction Assays: Applied in pull-down, co-immunoprecipitation (Co-IP), surface plasmon resonance (SPR) and biolayer interferometry (BLI) assays to verify, quantify and characterize the interaction between TEAD4 and YAP/TAZ, as well as other cofactors (VGLL, p300/CBP). This tool also enables screening for molecules that disrupt these critical protein-protein interactions.
3. In Vitro Transcriptional Activity Assays: Utilized in reporter gene assays and in vitro transcription systems to investigate TEAD4’s transcriptional activity, and to assess the regulatory effects of PTMs (e.g., palmitoylation) and small-molecule modulators on its functional output.
4. High-Throughput Drug Screening: Serves as a key reagent in high-throughput screening platforms to identify small-molecule inhibitors, peptide modulators and PROTAC degraders that target the TEAD4 YBD or inhibit TEAD4’s transcriptional activity.
5. Antibody Development and Validation: Used as an immunogen for the development of TEAD4-specific antibodies, and as a positive control to validate the specificity and affinity of anti-TEAD4 antibodies for use in cellular and clinical sample analysis.
6. Hippo Signaling Mechanistic Research: Employed to study the regulatory mechanism of the Hippo pathway on TEAD4 activity, and to elucidate the cross-talk between TEAD4 and other oncogenic signaling pathways in tumorigenesis and development.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.